More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor agonists offer neuroprotective and cerebrovascular benefits beyond what can ...

The technology, which led to a shift in strategy more than half of the time, could save $719 per symptomatic patient over 10 years.